BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schmidt RJ. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off? Expert Opinion on Pharmacotherapy 2009;10:1509-14. [DOI: 10.1517/14656560902997982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Alsalimy N, Awaisu A. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review. Int J Clin Pharm 2014;36:1115-25. [DOI: 10.1007/s11096-014-0023-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhang B, Towers EW, Poppe L, Cockrill SL. Analytical characterization of a novel degradation product in a PEGylated recombinant protein. Journal of Pharmaceutical Sciences 2011;100:4607-16. [DOI: 10.1002/jps.22661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
3 Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. Clinicoecon Outcomes Res 2014;6:319-30. [PMID: 25050070 DOI: 10.2147/CEOR.S46930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Schmid H. Peginesatide for the treatment of renal disease-induced anemia. Expert Opin Pharmacother 2013;14:937-48. [PMID: 23506424 DOI: 10.1517/14656566.2013.780695] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
5 Kessler M, Landais P, Bataille P, Yver L, Koné S, Kraemer S, Brillet G, Canivet E. [Anemia management in French hemodialysis patients: DiaNE study results at 3 years (DiaNE2)]. Nephrol Ther 2011;7:182-7. [PMID: 21227765 DOI: 10.1016/j.nephro.2010.11.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Schmid H. Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure. Expert Rev Hematol 2016;9:5-20. [PMID: 26573694 DOI: 10.1586/17474086.2016.1112734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]